Trial reportJournal of bone and mineral metabolism2010
The effects of weekly alendronate therapy in Taiwanese males with osteoporosis.
Trial report in Journal of bone and mineral metabolism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 8 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Comparative efficacy and safety of antiresorptive and anabolic therapies for male osteoporosis: an updated Bayesian network meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Comparative efficacy and safety of odanacatib, abaloparatide, denosumab, teriparatide, and bisphosphonates for male osteoporosis: a systematic review and network meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis.Frontiers in endocrinology · 2025Pooled it
- The efficacy and safety of denosumab, risedronate, alendronate and teriparatide to treat male osteoporosis: a systematic review and bayesian network meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis.Aging clinical and experimental research · 2023Pooled it
- Efficacy of anti-osteoporosis treatment for men with osteoporosis: a meta-analysis.Journal of bone and mineral metabolism · 2023Pooled it
- Local delivery therapies as adjuvants to non-surgical periodontal treatment of periodontitis grade C: a systematic review.Clinical oral investigations · 2020Pooled it
- Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Pooled it
- Male osteoporosis: pathophysiology, risk assessment, and evidence-based management.Turkish journal of medical sciences · 2026Review
- Inequities Across the Spectrum of Osteoporosis Care and Post-Fracture Management in Men.Current osteoporosis reports · 2025Review
- Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes.Drugs & aging · 2025Review
- Effect of Alendronate with β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial.Journal of clinical and diagnostic research : JCDR · 2016Article
- Article
- Vitamin D status in non-supplemented postmenopausal Taiwanese women with osteoporosis and fragility fracture.BMC musculoskeletal disorders · 2014Observational
- Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary.Journal of bone and mineral metabolism · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the efficacy, safety, and tolerability of weekly alendronate administration on male osteoporosis in Taiwan. This 6-month, randomized, open-label controlled trial enrolled 46 men with osteoporosis who were randomized to either 70 mg alendronate once weekly (n = 23) or control (n = 23). Bone mineral density (BMD) of lumbar spine and hip and biochemical bone turnover markers were measured; adverse events and tolerability were assessed. Subjects treated with alendronate showed a significant increase in BMD of 5.5% (vs. 2% in control group) at the lumbar spine and 2.7% (vs. 0.7%) at the femoral neck (P < 0.05) at 6 months, respectively. There were also significant decreases in serum level of bone formation marker (bone-specific alkaline phosphatase) and urinary excretion of bone resorption marker (deoxypyridinoline) at 3 and 6 months. Thus, alendronate showed anti-osteoporotic effects by increasing BMD and decreasing the concentrations of bone markers. The adverse events were mild and showed no significant difference between the two groups on safety assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.